UBS Group
MLYS icon

UBS Group’s Mineralys Therapeutics MLYS Stock Holding History

UBS Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.76M Buy
361,596
+263,567
+269% +$7.23M ﹤0.01% 3488
2026
Q1 		$2.66M Sell
98,029
-103,251
-51% -$3.03M ﹤0.01% 4708
2025
Q4 		$7.3M Buy
201,280
+111,776
+125% +$4.48M ﹤0.01% 3632
2025
Q3 		$3.39M Sell
89,504
-25,635
-22% -$554K ﹤0.01% 4441
2025
Q2 		$1.56M Buy
115,139
+77,978
+210% +$1.13M ﹤0.01% 5058
2025
Q1 		$590K Sell
37,161
-11,724
-24% -$135K ﹤0.01% 5720
2024
Q4 		$602K Buy
48,885
+32,785
+204% +$429K ﹤0.01% 5709
2024
Q3 		$195K Buy
16,100
+5,313
+49% +$64.3K ﹤0.01% 5894
2024
Q2 		$126K Sell
10,787
-8,932
-45% -$112K ﹤0.01% 6000
2024
Q1 		$255K Sell
19,719
-1,881
-9% -$23.2K ﹤0.01% 5686
2023
Q4 		$186K Buy
21,600
+14,099
+188% +$111K ﹤0.01% 5820
2023
Q3 		$71.3K Sell
7,501
-505
-6% -$6.58K ﹤0.01% 6067
2023
Q2 		$137K Buy
+8,006
New +$120K ﹤0.01% 5766

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group's MLYS Position: Q2 2026 in Review

UBS Group increased its Mineralys Therapeutics (MLYS) stake by 269% in Q2 2026, buying an estimated $7.23M and bringing the position to 361,596 shares worth $9.76M. The position accounts for ﹤0.01% of the portfolio, ranked #3488.

UBS Group first reported a position in MLYS in Q2 2023 and has held it in 13 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • UBS Group held 361,596 shares of Mineralys Therapeutics worth $9.76M as of Q2 2026.
  • UBS Group bought 263,567 Mineralys Therapeutics shares in Q2 2026, an estimated $7.23M.
  • Mineralys Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3488 holding.
  • UBS Group first reported a position in Mineralys Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.